NCT05223959

Brief Summary

Study objectives:

  1. 1.To determine the effectiveness of the CaPE intervention compared to treatment as usual (TAU) in reducing the time to recurrence for people with bipolar disorder (BD) I/II, currently in remission in Pakistan
  2. 2.To determine the impact of the CaPE intervention compared to TAU on clinical outcomes, quality of life and functioning; and
  3. 3.To estimate the cost-effectiveness of CaPE in a low-resource setting (i.e., Pakistan) (if the RCT confirms the effectiveness of CaPE in BD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
303

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 25, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 4, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

June 20, 2022

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 28, 2025

Completed
Last Updated

May 5, 2026

Status Verified

April 1, 2026

Enrollment Period

2.8 years

First QC Date

January 25, 2022

Last Update Submit

April 29, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Longitudinal Interval Follow-up Evaluation

    Longitudinal Interval Follow-up Evaluation (LIFE) is an integrated system for assessing the longitudinal course of psychiatric disorders. The assessment will consist of a semi-structured interview, during which an interviewer uses the LIFE to collect detailed psychosocial, psychopathologic, and treatment information for the follow-up interval. The weekly psychopathology measures are ordinal symptom-based scales with categories defined to match the criteria of the DSM-5.

    Change in scores from baseline to months 3, 6, and 12

Secondary Outcomes (8)

  • Demographic Questionnaire

    Baseline

  • Young Mania Rating Scale

    Change in scores from baseline to months 3, 6, and 12

  • Hamilton Depression Rating Scale

    Change in scores from baseline to months 3, 6, and 12

  • Quality of life scale

    Change in scores from baseline to months 3, 6, and 12

  • Bipolar Recovery Questionnaire

    Change in scores from baseline to months 3, 6, and 12

  • +3 more secondary outcomes

Study Arms (2)

CaPE Intervention

EXPERIMENTAL

CaPE is a manualized intervention consisting of 12 one-to-one psychoeducation sessions, one session per week. Each session will last for 60 minutes. All sessions will be delivered by a trained therapist who will receive two months training from senior therapists before starting intervention.

Behavioral: Culturally adapted Psychoeducation

Treatment as Usual

NO INTERVENTION

Treatment as usual (TAU) will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.

Interventions

This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).

CaPE Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult outpatients age 18 and above
  • Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) bipolar disorder (both BD I and BD II), currently in remission, confirmed by Structured Clinical Interview for DSM-5 (SCID)
  • Currently euthymic (Hamilton Depression Rating Scale, HDRS-17 \< 8 and Young Mania Rating Scale, YMRS \<8)
  • Able to give written informed consent
  • On stable psychiatric medication regimen for at least 3 months
  • Resident of the trial catchment area.

You may not qualify if:

  • Active substance use disorder, based on DSM-5 criteria
  • Currently experiencing recurrence (mania, hypomania, mixed or depressive
  • Active suicidal ideation
  • Unstable residential arrangements that reduce likelihood of being available for the duration of trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lahore General Hospital

Lahore, Select An Option…, 55000, Pakistan

Location

Related Publications (1)

  • Husain MI, Umer M, Asif M, Khoso AB, Kiran T, Ansari M, Aslam H, Bhatia MR, Dogar FA, Husain MO, Khan HA, Mufti AA, Mulsant BH, Naeem F, Naqvi HA, de Oliviera C, Siddiqui MS, Tamizuddin A, Wang W, Zaheer J, Husain N, Chaudhry N, Chaudhry IB. Culturally adapted psychoeducation for bipolar disorder in a low-resource setting: protocol for a multicentre randomised controlled trial. BJPsych Open. 2022 Nov 25;8(6):e206. doi: 10.1192/bjo.2022.598.

MeSH Terms

Conditions

Bipolar Disorder

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Study Officials

  • Muhammad Ishrat Husain, MD

    Centre for Addiction and Mental Health

    PRINCIPAL INVESTIGATOR
  • Nasim Chaudhry, MD

    Pakistan Institute of Living and Learning

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 25, 2022

First Posted

February 4, 2022

Study Start

June 20, 2022

Primary Completion

March 30, 2025

Study Completion

June 28, 2025

Last Updated

May 5, 2026

Record last verified: 2026-04

Locations